ArticleNutrition & metabolism2025
Cinnamic acid improves insulin sensitivity in prediabetic mice through branched-chain amino acid metabolic reprogramming.
Article in Nutrition & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundInsulin resistance is a key pathological feature in the early stages of type 2 diabetes mellitus (T2DM), often associated with obesity and metabolic dysfunction. Cinnamic acid (CA) is a natural compound found abundantly in cinnamon and other dietary sources, has demonstrated antidiabetic potential. However, its preventive role in improving insulin sensitivity during the prediabetic stage and the underlying mechanisms remain poorly understood.
methodsThis study evaluated the preventive effects of cinnamic acid in a high-fat diet (HFD)-induced prediabetic mouse model. Male C57BL/6 N mice were divided into control and intervention groups and treated with CA for 12 weeks. Glucose and insulin tolerance tests, histopathological analysis, serum biochemistry, transcriptomics, metabolomics, and molecular docking and dynamics simulations were performed.
resultsCA significantly improved glucose tolerance, lowered fasting glucose and improved insulin sensitivity, and reduced adiposity in HFD-fed mice. Integrated transcriptomic and metabolomic analyses indicated enhanced branched-chain amino acid (BCAA) degradation in adipose tissue following CA treatment, marked by upregulation of key metabolic enzymes and decreased local and systemic BCAA levels. Molecular docking and dynamics confirmed stable binding between CA and target enzymes involved in BCAA catabolism. Furthermore, CA reduced inflammatory markers, increased adiponectin signaling, and restored GLUT4 expression in adipose tissue.
conclusionsCA prevents HFD-induced impairment of insulin sensitivity in prediabetic mice by promoting BCAA catabolism and alleviating adipose inflammation. These findings support its potential as a safe and cost-effective nutrition-based intervention for early prevention of metabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.